Nasdaq
$19.80▲ 0.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $392.4MShares out 19.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
3- 8.20After-hours26.08.21 05:30S-8Offering#●●●#●●●
ASSEMBLY BIOSCIENCES, INC.
Assembly Biosciences has registered an additional 1,490,000 shares of common stock for its 2018 Stock Incentive Plan and the 2018 Employee Stock Purchase Plan (ESPP). Specifically, 1,200,000 shares were reserved for the 2018 Plan and 290,000 shares for the ESPP to support employee compensation and stock purchase programs.…more
$19.80+0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.13Regular26.08.14 01:47SCHEDULE 13G/AOwnership
ASSEMBLY BIOSCIENCES, INC.
Janus Henderson Group Ltd. has filed a power of attorney appointing Kristin Mariani and Caroline Barotti as its attorneys-in-fact to handle SEC reporting requirements. This filing formalizes the administrative process for managing ownership and control-person reporting for Janus Henderson and its 13 affiliated asset managers.…more
$19.80+0.13%vs prev closeView filingShare - 8.4Pre-market26.08.04 21:29SCHEDULE 13G/AOwnership
ASSEMBLY BIOSCIENCES, INC.
Farallon Capital Management, L.L.C.와 관련 개인들이 Assembly Biosciences, Inc.에 대한 공동 지분 보유 사실을 확인하는 Schedule 13G 공동 취득 성명서를 제출했습니다. 이는 해당 투자자들이 회사의 지분을 공동으로 관리 및 보고하기 위한 법적 절차를 완료했음을 의미합니다.…more
$19.80+0.13%vs prev closeView filingShare
2 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.5Regular26.10.05 23:00#●●●#●●●#●●●
Assembly Biosciences Reports Positive Phase 1a Data for ABI-6250
Assembly Biosciences announced positive safety and pharmacodynamic data for its liver disease candidate ABI-6250 from a Phase 1a study. The company plans to advance the drug into Phase 2 clinical trials for chronic HDV infection starting in the fourth quarter of 2026.…more
$19.80+0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.10After-hours26.09.11 05:15
●●●●●●●● ●●●●● ●●●●●●
Assembly Biosciences announced that its senior management will present at the upcoming H.C. Wainwright & Co. Global Investment Conference. This event is a standard corporate presentation and does not contain immediate material catalysts for the stock.…more
$19.80+0.13%vs prev close - 9.8After-hours26.09.09 05:17
●●●●●●●● ●●●●● ●●●●●●
Assembly Biosciences is eligible for up to $280 million in milestones and royalties outside the U.S. and expects to advance its genital herpes treatment to Phase 2 by late 2026, with cash runway extending into 2029.…more
$19.80+0.13%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report